Business
QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)
Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO, July 14,
About this update from Quidelortho Corporation
[{"type":"text","content":"Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms\nSAN DIEGO, July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (\"QuidelOrtho\") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.\n\n \n \n \n \n \n \n\n \nThis collaboration addresses key healthcare trends, including the rise of non-invasive diagnostic tools, the demand for cost-effective healthcare solutions, and the growing focus on gastrointestinal and pancreatic health and its systemic impact. The fCAL and fPELA turbo assays exemplify innovation in diagnostics technology, supporting the shift toward tailored medicine and preventive healthcare.\nThe fCAL and fPELA turbo assays are both now available for use on QuidelOrtho's VITROS Systems (fCAL turbo and fPELA turbo assays – U.S. and Outside U.S.: VITROS XT 7600 and 5600 Integrated System, as well as VITROS 4600 Chemistry Systems.\nKey features include:\nRapid results in less than 10 minutesWide reportable ranges90-day on-analyzer stabilityCompatibility with VITROS Automation SolutionsSimplified sample extraction and preparation with CALEX® Cap technology\"The integration of BÜHLMANN's fCAL and fPELA turbo assays with our VITROS Systems represents a significant advancement in IBD and pancreatic insufficiency diagnoses,\" said Jonathan Siegrist, PhD, Executive Vice President of Research & Development & Chief Technology Officer at QuidelOrtho. \"This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues. With features like the long calibration interval and the ability to use the CALEX Cap–prepared stool samples directly, we're offering a solution that combines clinical accuracy with operational efficiency, ultimately improving patient care.\"\nThese assays contribute to better management of gastrointestinal health, reducing the...